Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-15T01:29:46.314Z Has data issue: false hasContentIssue false
  • English
  • Français

Seroconversion Rates in Healthcare Workers Using a Latex Agglutination Assay After Varicella Virus Vaccination

Published online by Cambridge University Press:  02 January 2015

David M. Weinstock ,
Maureen Rogers ,
Suzanne Lim ,
Janet Eagan  and
Kent A. Sepkowitz
David M. Weinstock
Affiliation:
Department of Medicine, New York Hospital-Cornell University Medical Center, New York City, New York
Maureen Rogers
Affiliation:
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell University Medical Center, New York City, New York
Suzanne Lim
Affiliation:
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell University Medical Center, New York City, New York
Janet Eagan
Affiliation:
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell University Medical Center, New York City, New York
Kent A. Sepkowitz*
Affiliation:
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell University Medical Center, New York City, New York Department of Medicine, New York Hospital-Cornell University Medical Center, New York City, New York
*
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To determine the seroconversion rate after varicella immunization of healthcare workers (HCWs) and the effect of seroconversion rate on current cost-based recommendations for universal vaccination.

Methods:

A voluntary vaccination program for HCWs was performed at a tertiary-care cancer center in New York City. A commercial latex agglutination assay was used to test postvaccination antibody response. Costs for vaccination and postvaccination serological testing were compared to potential costs of postexposure employee furloughs.

Results:

Of 263 seronegative HCWs, 96 (36.5%) began the vaccine program. Thirty-nine HCWs received only one dose of vaccine. Seven returned for follow-up antibody testing, of whom 4 were seropositive. Of the 57 HCWs who received two doses, 38 returned for follow-up serology. Thirty-one (81.6%) HCWs were seropositive for varicella-zoster virus antibodies, and seven HCWs (18.4%) remained seronegative. Total cost of vaccination for all 263 seronegative HCWs was estimated and compared to the cost of varicella-related furloughs at our institution.

Conclusions:

We found a considerably lower rate of vaccine-induced seroconversion at our hospital compared to that of the published literature. Despite this finding, universal varicella vaccination remained an extremely cost-effective alternative to the furloughing of exposed, seronegative HCWs. Projected hospital savings exceeded $53,000 in the first year after vaccination alone.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 7 , July 1999 , pp. 504 - 507
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices. MMWR 1996;45(RR-11):1–36.Google Scholar
2.Gordon, JE, Meader, FM. The period of infectivity and serum prevention of chickenpox. JAMA 1929:290:2013–2015.Google Scholar
3.Krasinski, K, Holzman, RS, LaCouture, R, Florman, A. Hospital experience with varicella-zoster virus. Infect Control 1986;7:312–316.CrossRefGoogle ScholarPubMed
4.Centers for Disease Control and Prevention. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(RR-18):11-13,25–26.Google Scholar
5.Tennenberg, AM, Brassard, JE, Van Lieu, J, Drusin, LM. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect Control Hosp Epidemiol 1997;18:405–411.CrossRefGoogle Scholar
6.Nettleman, MD, Schmid, MS. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol 1997;18:504–508.CrossRefGoogle ScholarPubMed
7.Weber, DJ, Rutala, WA, Hamilton, H. Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol 1996;17:694–705.Google ScholarPubMed
8.Wasmuth, EH, Miller, WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990;32:189–193.Google ScholarPubMed
9.Varivax package insert. Merck & Co, Inc: West Point, PA 1995.Google Scholar
10.Landry, ML, Ferguson, D. Comparison of latex agglutination test with enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus. J Clin Microbiol 1993;31:3031–3033.CrossRefGoogle ScholarPubMed
11.Krah, DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am 1996;10:507–527.CrossRefGoogle ScholarPubMed
12.VZVScan package insert. Becton-Dickson: Meylan, France; 1995.Google Scholar
13.Gershon, AA, Steinberg, SP, LaRussa, P, Ferrara, A, Hammerschlag, M, Gelb, L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132–137.CrossRefGoogle ScholarPubMed
14.Varicella vaccine. Medical Letter 1995;37:55–57.Google Scholar
15.Kuter, BJ, Ngai, A, Patterson, CM, Staehle, BO, Cho, I, Matthews, H, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995;13:967–972.CrossRefGoogle ScholarPubMed
16.Johnson, CE, Stancin, T, Fattlar, D, Rome, LP, Kumar, ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997;100:761–766.CrossRefGoogle ScholarPubMed
17.Zerboni, L, Nader, S, Aoki, K, Aran, AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998;177:1701–1704.CrossRefGoogle ScholarPubMed
18.Preblud, SR. Nosocomial varicella: worth preventing, but how? Am J Public Health 1988;78:13–15.CrossRefGoogle Scholar
19.Gershon, AA, LaRusssa, P, Hardy, I, Steinberg, S, Silverstein, S. Varicella vaccine: the American experience. J Infect Dis 1992;166(suppl 1):S63–S68.CrossRefGoogle ScholarPubMed